We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Skewed Caspase-9 Expression Drives Tumorigenicity of Lung Cancer Cells

By LabMedica International staff writers
Posted on 22 Dec 2010
Print article
The ability of non-small-cell lung cancer (NSCLC) cells to form tumors and spread is controlled by variations in RNA expression that determine the ratio of pro- and anti-apoptotic forms of the enzyme caspase-9.

Caspase-9 is involved in the intrinsic apoptotic pathway, and it has been implicated as playing a role as a tumor suppressor. However, so far little is known about the mechanisms governing caspase-9 expression.

Investigators at Virginia Commonwealth University (Richmond, USA) worked with a model system in which human NSCLC cells were transplanted into mice. They manipulated this model by using virus-based targeted gene therapy to reduce the amount of heterogeneous nuclear ribonuclear protein family member L (hnRNP L) in the NSCLC cells. HnRNP L is a member of the hnRNP family of RNA processing factors and regulates the expression of two caspase-9 variants, the proapoptotic caspase-a and the antiapoptotic caspase-b, through a process known as RNA splicing.

Results published in the October 25, 2010, online edition of the Journal of Clinical Investigation revealed that the ratio of caspase-9a to caspase-9b differed markedly between normal lung cells and NSCLC cells. Increased caspase-9b in NSCLC cells acted to promote tumor formation, growth, and maintenance. Gene therapy that caused the downregulation of hnRNP L in NSCLC cells induced a complete loss of tumorigenic capacity that was due to the changes in caspase-9 introduced prior to RNA processing. This effect was demonstrated at the molecular level by the finding that hnRNP was specifically phosphorylated in NSCLC. The phosphorylated hnRNP L, in turn, promoted expression the antiapoptotic caspase-9b, thereby contributing to tumorigenesis.

"We are researching an unexplored area of RNA splicing factors in relation to cancer,” said senior author Dr. Charles E. Chalfant, associate professor of biochemistry and molecular biology at Virginia Commonwealth University. "Before this study, there had been very little evidence of an RNA splicing event that results in cancerous tumor development. This study points to caspase-9b as being a very important target in the development of a durable therapy for non-small-cell lung cancer.”

"Unfortunately, many current therapies for lung cancer are less effective and more toxic than we would like,” said Dr. Chalfant. "Lung cancer kills more people than any other cancer, and there is a real need for new cellular targets that are cancer-specific and show results in large numbers of patients regardless of the mutations found in individual tumors. Since caspase-9b is mainly expressed in malignant cells, these findings may provide innovative treatments for non-small-cell lung cancer with little to no toxic side effects.”

Related Links:

Virginia Commonwealth University



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.